The role of intensive chemotherapy in myelodysplastic syndromes.

abstract：:A leukemia-associated CD9 glycoprotein antigen released into the extracellular milieu from acute lymphoblastic leukemia cells has been detected using a unique lectin-monoclonal antibody immunoassay. It has been demonstrated that the release of CD9 antigen is an active process and is associated with active cell growth....

journal_title：Leukemia & lymphoma

authors： Komada Y,Sakurai M

更新日期：1994-02-01 00:00:00

abstract：:It is unknown whether rituximab increases the risk of second primary malignancies (SPMs) in patients with diffuse large cell B-cell lymphoma (DLBCL). We assessed SPMs in DLBCL patients diagnosed between 1996 and 2014 in comparison with the general Israeli population and dependent on rituximab treatment. Jewish patient...

journal_title：Leukemia & lymphoma

authors： Neeman Y,Perry C,Silverman B,Waintraub N,Avivi I

更新日期：2020-11-01 00:00:00

abstract：:FB2 is a novel Abl/Src dual tyrosine kinase inhibitor which is designed to overcome imatinib resistance. Besides imatinib-sensitive cell lines (K562), FB2 significantly inhibited the growth of imatinib-resistant cell lines of different resistance mechanisms (K562/G5.0 and K562/G01), and decreased the expression of aut...

journal_title：Leukemia & lymphoma

authors： Liu H,Li H,Feng Z,Tai J,Meng Y,Wang H,Xin H,Zhang S,Zuo M,Zhang Y,Chen X

更新日期：2009-03-01 00:00:00

abstract：:The occurrence of unexplained peripheral blood cytopenia, particularly neutropenia, has been recently reported after rituximab. Its prevalence may be underestimated since it may occur late after treatment. This study analysed all cases of unexplained delayed-onset peripheral blood cytopenia of WHO grade II - IV occurr...

journal_title：Leukemia & lymphoma

authors： Cattaneo C,Spedini P,Casari S,Re A,Tucci A,Borlenghi E,Ungari M,Ruggeri G,Rossi G

更新日期：2006-06-01 00:00:00

abstract：:We have previously described a relation between abundance of eosinophilic granulocytes in Hodgkin's disease (HD) tumours and poor prognosis. In order to further explore the importance of the eosinophilic infiltration, we immunohistochemically examined the presence of eosinophils, using the monoclonal antibodies EG 1 a...

journal_title：Leukemia & lymphoma

authors： Molin D,Glimelius B,Sundström C,Venge P,Enblad G

更新日期：2001-07-01 00:00:00

abstract：:Chemotherapy has long been integral to the treatment of chronic lymphocytic leukemia (CLL). Fludarabine/cyclophosphamide, chlorambucil and bendamustine are commonly used as a backbone, depending on the patient's age and general health. The advent of the anti-CD20 monoclonal antibodies, such as rituximab and obinutuzum...

journal_title：Leukemia & lymphoma

authors： Wendtner CM,Gregor M

更新日期：2018-02-01 00:00:00

abstract：:Autocrine Motility Factor (AMF)/maturation factor (MF)/neuroleukin (NLK) is a multifunctional protein, which acts as a glucose 6-phosphate isomerase (G6PI) intracellularly. Exto-G6PI stimulates invasion and metastasis of tumor cells, neurotropic growth and differentiation of leukemic cells. The cell motility and proli...

journal_title：Leukemia & lymphoma

authors： Haga A,Komazaki S,Funasaka T,Hashimoto K,Yokoyama Y,Watanabe H,Raz A,Nagase H

更新日期：2006-10-01 00:00:00

abstract：:High dose cytosine arabinoside (ARA-C) has produced long term relapse free survival in 26% to 49% of patients when used as consolidation therapy of acute non-lymphocytic leukemia (ANLL) in first remission. However, the optimal consolidation regimen has not been defined. In this pilot study we attempted to confirm and ...

journal_title：Leukemia & lymphoma

authors： Stein RS,Greer JP,Flexner JM,Goodman S,Wolff SN

更新日期：1996-09-01 00:00:00

abstract：:Herbal remedies are clearly a complementary and alternative modality used frequently by patients with hemato-oncological neoplasias during the course of their specific treatment. This review focuses on the potential safety and efficacy of herbs which are either used often or even on a daily basis by patients with hema...

journal_title：Leukemia & lymphoma

authors： Ben-Arye E,Attias S,Tadmor T,Schiff E

更新日期：2010-08-01 00:00:00

abstract：:A possible role for DNA mismatch repair defects and microsatellite instability (MSI) in the pathogenesis of a number of B-cell lymphoproliferative disorders has recently been debated. To gain further insight into the impact of MSI on B-CLL, we evaluated samples from a series of 982 patients using the mono-satellite ma...

journal_title：Leukemia & lymphoma

authors： Sellick GS,Lubbe SJ,Matutes E,Catovsky D,Houlston RS

更新日期：2007-07-01 00:00:00

abstract：:The MRC has conducted randomised trials in CLL sine 1978: CLL 1 (1978-84), 660 patients; CLL 2 (1984-90), 640 patients; CLL 3 (from June 1990), 90 patients. Centralised morphological diagnosis and membrane marker studies have allowed the exclusion of non-CLL disorders. Some of the treatment questions were repeated in ...

journal_title：Leukemia & lymphoma

authors： Catovsky D,Richards S,Fooks J,Hamblin TJ

更新日期：1991-01-01 00:00:00

abstract：:Granulocyte-colony stimulating factors (G-CSFs) enhance bone marrow (BM) recovery after autologous stem cell transplant (ASCT) in patients with lymphoma and myeloma. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study in patients with lymph...

journal_title：Leukemia & lymphoma

authors： Ianotto JC,Ngo Sack F,Couturier MA,Tempescul A,Mugnier N,Delepine P,Guillerm G,Berthou C

更新日期：2014-01-01 00:00:00

abstract：:The bone marrow microenvironment is a complex three dimensional structure where hematopoietic stem cells proliferate, mature, migrate into the sinusoidal space, and enter the circulation in an exquisitely regulated fashion. Stromal cells within the BM microenvironment provide a suitable environment for self-renewal, p...

journal_title：Leukemia & lymphoma

authors： Rafii S,Mohle R,Shapiro F,Frey BM,Moore MA

更新日期：1997-11-01 00:00:00

abstract：:The prognostic significance of immunophenotype and other features including sex, age, anaemia, WBC, FAB type, and PAS staining were analysed in a group of 389 children newly diagnosed as acute lymphoblastic leukemia (ALL) and treated according to the BFM 1981/1983 protocol. The CR rate was higher (82-94%) in immunophe...

journal_title：Leukemia & lymphoma

authors： Holowiecki J,Koehler M,Zintl Z,Kardos G,Lutz D,Krzemien S,Rewesz T,Brugiatelli M,Callea V,Kachel L

更新日期：1992-06-01 00:00:00

abstract：:Infectious complications following treatment of acute myeloid leukemia (AML) are important causes of morbidity and mortality. The spectrum and complexity of these infections is reflected by the severe net state of immunosuppression of AML patients, that is dynamic and continuously changing, the polypharmacy, including...

journal_title：Leukemia & lymphoma

authors： Mulanovich V,Kontoyiannis DP

更新日期：2018-06-01 00:00:00

abstract：:MDSCs, which are defined as a kind of negatively regulatory cells, could suppress T cell immune response in many tumor-bearing animal models and cancer patients. We supposed that MDSCs also contributed to the impaired antitumor immunity in MDS. Here we demonstrated that STAT3-ARG1 pathway could be a critical signal tr...

journal_title：Leukemia & lymphoma

authors： Qi X,Jiang H,Liu P,Xie N,Fu R,Wang H,Liu C,Zhang T,Wang H,Shao Z

更新日期：2021-01-01 00:00:00

abstract：:Donor T cells have a critical role in promoting engraftment after allogeneic bone marrow transplantation (BMT), but also cause graft versus host disease (GVHD). Ex vivo T cell depletion has been an effective strategy to reduce GVHD but has been associated with impaired alloengraftment and host immunity. Using an MHC-m...

journal_title：Leukemia & lymphoma

authors： Drobyski WR,Gendelman M

更新日期：2002-10-01 00:00:00

abstract：:Ponatinib is a pan-tyrosine kinase inhibitor (TKI) with efficacy in multirefractory CML patients who have failed other TKIs. Despite excellent response rates, resistance or intolerance may develop. We conducted a retrospective review of the outcome of patients with chronic (CP) and accelerated (AP) phase CML refractor...

journal_title：Leukemia & lymphoma

authors： Boddu P,Shah AR,Borthakur G,Verstovsek S,Garcia-Manero G,Daver N,Kadia T,Ravandi F,Jain N,Alhuraiji A,Burger J,Kornblau S,Pierce S,Dellasala S,Jabbour E,Kantarjian H,Cortes J

更新日期：2018-06-01 00:00:00

abstract：:Peripheral T-cell lymphomas are characterized by a poor clinical outcome. We retrospectively analyzed 208 adults treated in our institution between 2000 and 2011. Median age at diagnosis was 55 years. Fifty-one percent had B symptoms and 51% serum elevated lactate dehydrogenase (LDH) levels. Eastern Cooperative Oncolo...

journal_title：Leukemia & lymphoma

authors： Broussais-Guillaumot F,Coso D,Belmecheri N,Ivanov V,Schiano de Collela JM,Aurran-Schleinitz T,Stoppa AM,Chetaille B,Xerri L,Esterni B,Blaise D,Bouabdallah R

更新日期：2013-11-01 00:00:00

abstract：:Primary non-Hodgkin's lymphoma of bone is uncommon and usually manifests clinically as localized bone pain. Here we report a woman who presented with hypercalcemic crisis and extensive investigation revealed a primary multifocal lymphoma of bone. The course of the disease was very aggressive and despite intensive supp...

journal_title：Leukemia & lymphoma

authors： Evron E,Goland S,Klepfish A,Malnick SD,Sokolowski N,Sthoeger ZM

更新日期：1999-06-01 00:00:00

abstract：:Chronic exposure to high concentrations of benzene is associated with an increased incidence of myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Studies of patients occupationally exposed to benzene show a pattern of cytogenetic aberrations involving loss of all or part of chromosomes 5 and/or 7 as...

journal_title：Leukemia & lymphoma

authors： Stillman WS,Varella-Garcia M,Irons RD

更新日期：1999-10-01 00:00:00

abstract：:Chimeric antigen receptor-modified T-cells (CART) are a potent and targeted immunotherapy which have induced remissions in some patients with chemotherapy refractory or relapsed (RR) hematologic malignancies. Hundreds of patients have now been treated worldwide with anti-CD19 CART cells, with complete response rates o...

journal_title：Leukemia & lymphoma

authors： Cummins KD,Gill S

更新日期：2018-07-01 00:00:00

abstract：:From July 1983 to January 1991 a total of 622 patients were randomized (585 eligible) to compare the effects of hydroxyurea, interferon alpha (IFN), and busulfan on the duration of chronic phase, and survival. Further goals included the determination of prognostic parameters. 598 CML patients were documented and 575 e...

journal_title：Leukemia & lymphoma

authors： Hehlmann R,Heimpel H,Kolb HJ,Heinze B,Hochhaus A,Griesshammer M,Pralle H,Queisser WP,Essers U,Falge C

更新日期：1993-01-01 00:00:00

abstract：:A prospective randomized study on aggressive non-Hodgkin's lymphomas was conducted by investigators at several Italian institutions with the intent of comparing two third-generation conceptually different regimens: the regimen containing methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, ...

journal_title：Leukemia & lymphoma

authors： Mazza P,Zinzani PL,Martelli M,Fiacchini M,Bocchia M,Pileri S,Falini B,Martelli MF,Amadori S,Papa G

更新日期：1995-02-01 00:00:00

abstract：:Acute graft-versus-host-disease (aGVHD) is a frequent and often lethal complication of allogeneic hematopoietic stem cell transplant despite prophylaxis. Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody that has evidence of activity in patients with steroid refractory (SR) GVHD. We retrospectively rep...

journal_title：Leukemia & lymphoma

authors： Roddy JV,Haverkos BM,McBride A,Leininger KM,Jaglowski S,Penza S,Klisovic R,Blum W,Vasu S,Hofmeister CC,Benson DM,Andritsos LA,Devine SM,Efebera YA

更新日期：2016-01-01 00:00:00

abstract：:Natural killer (NK) cells are the subject of great current interest because of their possible (in vivo) role in tumour cell surveillance and killing, and because of the potential application of cytokine-modulated NK cells in cancer immunotherapy. In addition, clonal proliferations of NK-associated (NKa) cell populatio...

journal_title：Leukemia & lymphoma

authors： Richards SJ,Scott CS

更新日期：1992-08-01 00:00:00

abstract：:Using a non-myeloablative stem cell trasplantation (NST) program, 25 allografts were prospectively given to 24 patients with acute myelogenous leukemia (AML) eligible for conventional allografting; 2 individuals had secondary forms of AML. The median age of the patients was 35 years, with a range of 12 to 56. All pati...

journal_title：Leukemia & lymphoma

authors： Ruiz-Argüelles GJ,Gómez-Almaguer D,David-Gomez-Rangel J,Vela-Ojeda J,Cantú-Rodríguez OG,Jaime-Pérez JC,González-Llano O,Herrera-Garza JL

更新日期：2004-06-01 00:00:00

abstract：:Rituximab is a CD20-targeted monoclonal antibody widely used in the treatment of B-cell lymphoma. Previously, we have shown that Epstein-Barr virus (EBV) latent membrane protein-1 (LMP1) increases chemoresistance in malignant cancer cells. In this study we examined the effects of LMP1 on the response of B-cell lymphom...

journal_title：Leukemia & lymphoma

authors： Kim JH,Kim WS,Park C

更新日期：2012-08-01 00:00:00

abstract：:Normal, bi-directional interactions between CD 40 and its natural ligand CD 154 (CD 40 ligand) are central to the generation of both T cell-dependent, humoral immune responses and cytotoxic T-cell responses. CD 40 is expressed on a broad range of hematological and epithelial malignancies. The development of monoclonal...

journal_title：Leukemia & lymphoma

authors： Geldart T,Illidge T

更新日期：2005-08-01 00:00:00

abstract：:Multiple myeloma is a B-cell malignancy with a highly variable outcome. Despite the marked recent improvements in its management, especially due to the widespread application of high-dose treatment and autologous stem cell transplantation, relapses eventually occur in the majority of patients. Systematic research at U...

journal_title：Leukemia & lymphoma

authors： Fassas AB,Van Rhee F,Tricot G

更新日期：2003-05-01 00:00:00